It is estimated that nearly 50-70 percent patients in India do not adhere to asthma treatment regimen recommended by a doctor. Up to 50 percent of such non-adherence is on account of the patient’s forgetfulness to take medicines on time and due to inadequate understanding of the prescribed treatment regimen. Sun Pharma’s RespiTrack aims to address these and other reasons leading to non-adherence thereby improving compliance to asthma treatment through recurring medication reminders, pre-programmed alerts, over-the-air review by the doctor etc.
Abhay Gandhi, CEO - India Business, Sun Pharma said, “Unlike other chronic illnesses where non-adherence to treatment regimen could have significant impact on the patient’s health, asthmatics tend to be low on the short-run adversity impact of non-adherence. However, in the long run, the implications of non-adherence to prescribed asthma treatment can severely impede quality of life of these patients. By leveraging our digital technology capabilities, we believe RespiTrack can address this unmet need by reducing non-adherences incidences to treatment.”
For an asthma patient, RespiTrack allows complete monitoring of asthma attacks, symptoms and medications prescribed by the physician. It enables these patients to record time, place, duration & triggers of attacks along with medication details on the mobile app. The patient can easily send this data to the consulting physician through over-the-air mode on a weekly or monthly basis. RespiTrack also offers a review dashboard that gives a snapshot of all parameters to monitor over a period of time.
Through RespiTrack, a doctor can access his patient’s details through a personalised tracker module which is directly synced with the patient’s App. This module allows doctors to access patient’s ailment history, attack patterns, symptoms, medication patterns and reports. A doctor can remotely view patient reports and also connect with them through an integrated messaging app.
As per WHO Report, India has an estimated 15-20 million asthmatic patients. Various studies estimate that nearly 40% of Asthma patients use inhalers and the rest prefer oral formulations.
Sun Pharma’s RespiTrack is available on Google Play Store & Apple Store. A patient needs a Registration Number issued by his/her doctor to use this app.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)